Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus ELOCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus ELOCON.
CAPEX vs ELOCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Elocon (mometasone furoate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to increased synthesis of lipocortins that inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene formation. It also suppresses cytokine production and inflammatory cell migration.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Apply a thin film to affected skin area once daily. Use no more than 45 g per week.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life approximately 5-7 hours after topical application. Systemic half-life is short, limiting systemic accumulation with topical use.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily hepatic metabolism; metabolites excreted renally and in feces. Approximately 60% of a topical dose is excreted in urine as metabolites, 30% in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid